A2 Healthcare

Name

A2 Healthcare

Legal name

A2 Healthcare Corporation

Website

https://a2healthcare.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Clinical development services
• Contract research organization
• Pharmaceutical development
• Post-marketing surveillance
• Medical device development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Development Services (CRO): A2 Healthcare operates as a full-service Contract Research Organization (CRO), providing comprehensive clinical development solutions to pharmaceutical and medical device companies. Services span the entire drug development lifecycle from early-phase clinical trials through post-marketing surveillance, including monitoring, data management, statistical analysis, regulatory affairs, and specialized services in oncology, regenerative medicine, vaccines, and medical devices.
2. DrugLifecycle Management /育薬事業: Post-marketing surveillance (PMS) monitoring services as a second pillar of business following the acquisition of Farfield's PMS monitoring business. This includes pharmacovigilance, PMS support, and lifecycle management services.
3. J-STEP (Japan Market Entry Support): Comprehensive support services for foreign biotech companies entering Japan, including regulatory consulting, site setup, manufacturing strategy, distribution, and commercialization coordination.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

A2 Healthcare is a full-service Contract Research Organization (CRO) providing comprehensive clinical development solutions for pharmaceutical, medical device, and regenerative medicine companies. Services span the entire drug development lifecycle, from Phase I–IV clinical trials and post-marketing surveillance (PMS) through to regulatory affairs, statistical analysis, data management, and Japan market entry support for foreign biotech firms via its proprietary J-STEP platform.

Product overview

A2 Healthcare is a full-service CRO providing comprehensive clinical development solutions as both a platform and integrated service portfolio. The core offering consists of drug development services spanning project management, data management, monitoring, statistical analysis, quality management, and regulatory affairs, delivered alongside specialized therapeutic offerings including oncology, regenerative medicine, vaccine development, and medical devices. Key platform components include proprietary m-EDC (electronic data capture), the award-winning Kondo-method RBM system, and DCT (decentralized clinical trial) capabilities. J-STEP serves as the flagship market entry program for foreign companies, while post-marketing surveillance and pharmacometric services complete the development lifecycle. The company operates globally with offices in Tokyo, Osaka, Taiwan, and Boston, leveraging partnerships with Viedoc, Spotfire, SAS, TriNetX, and Certara to deliver integrated solutions.

Differentiator

Problem solved

Functional benefit

Brands

• J-STEP (Japan Strategic Teaming & Entry Program): Comprehensive support service designed to help foreign biotech companies navigate Japan's pharmaceutical market and clinical trial ecosystem, providing regulatory consulting, site setup, manufacturing strategy, distribution, and commercialization support

Products and services

• Drug Development Services (医薬品開発)

Quantifiable outcome

• Kondo-method reduces monitoring scope and frequency while ensuring patient safety and data quality - recognized by 2022 DIA Global Inspire Award
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability6 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and secondary.

• Farfield Corporation (事業譲受)coreOthers · 1 November 2025Business acquisition from Farfield Corporation (Tokyo, President: Yamaguchi Tsukasa) effective November 1, 2025. Acquired PMS monitoring business and nationwide network of PMS monitors to strengthen drug lifecycle management (育薬事業) as second pillar alongside clinical development services.
• Axcelead, Inc.coreStrategic or Co-development Partner · 16 June 2025Business partnership with Axcelead, Inc. (Tokyo) to provide seamless pharmaceutical R&D support in Japan. Axcelead offers drug discovery platform services through Axcelead Drug Discovery Partners (Fujisawa) and mRNA vaccine manufacturing through ARCALIS (Minamisoma). This partnership enables end-to-end support from drug discovery through clinical development and regulatory approval.
• Vitalive CorporationsecondaryStrategic or Co-development Partner · 23 May 2025Collaboration with Vitalive (Tokyo, founded 2024) to promote VitaliveOS, a platform for digitizing survival surveys in oncology clinical trials using SMS-based automated surveys. This partnership aims to reduce burden on clinical staff and improve efficiency in survival follow-up procedures. VitaliveOS enables automatic data collection without phone calls.
• Certara, Inc.coreTechnology or Integration · 8 April 2025Partnership with Certara, Inc. (Nasdaq: CERT, Pennsylvania, USA) to strengthen drug development and regulatory software offerings in the Japanese market. A2 Healthcare will leverage Certara's software suite including CoAuthor, CODEx, Phoenix, Pinnacle, and DIDB to optimize regulatory strategy and accelerate submission processes. The partnership supports Model-Informed Drug Development (MIDD) consulting services.
• Viedoc Technologies ABcoreStrategic or Co-development Partner · 26 February 2025Co-development partnership with Viedoc Technologies AB (Uppsala, Sweden) to implement A2 Healthcare's proprietary 'Kondo-method' for Risk-Based Monitoring (RBM) into Viedoc's next-generation RBM solution. This collaboration aims to provide evidence-based reduction in monitoring scope and frequency across clinical trials globally. The Kondo-method received the 2022 DIA Global Inspire Award for Author of the Year. Release planned for late 2025.
• TXP MedicalsecondaryTechnology or Integration · 1 June 2021Partnership to conduct Japan's first clinical trial recruitment using TXP Medical's Next Stage ER system. Supports efficient patient recruitment for domestic clinical trials.
• Bell System 24secondaryChannel Partner/ Reseller/ Distributor · 8 September 2020Strengthened cooperation for outsourcing services to pharmaceutical companies in the new normal era. Partnership for new outsourcing services combining clinical development expertise with contact center capabilities.
• iLAC Inc.secondaryTechnology or Integration · 23 June 2020Business partnership to offer whole genome analysis services as Japan's first CRO service including complete genome analysis. Provides advanced genomic analysis capabilities for clinical development.
• 3H Medi Solution CorporationsecondaryStrategic or Co-development Partner · 11 November 2019Business partnership initiated November 2019 based on Patient Centricity for drug development support. 3H Medi Solution operates cancer information website 'Oncolo' and co-hosts cancer education seminars including Osaka Oncology Seminar Night School, ONCOLO Meets Cancer Experts, and Kasai Shinsuke's 'Can I Ask This?' program.
• TriNetXsecondaryTechnology or Integration · 8 November 2019Service partnership to provide Real-World Data (RWD) investigation services using TriNetX's global RWD network. Enables evidence generation and clinical trial support through real-world data analytics.
• ICON plcsecondaryStrategic or Co-development Partner · 20 April 2011International joint trial service partnership with global CRO ICON plc for international multi-center trial support. Enables A2 Healthcare to offer global clinical trial capabilities through ICON's international network.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Parexel International: Global full-service CRO with strong Asia-Pacific presence including Japan operations. Broad incumbent offering Phase I-IV clinical development, regulatory consulting, and post-marketing services — directly overlapping A2's full-service portfolio but at significantly greater scale.
• IQVIA: World's largest CRO combining clinical research services with real-world evidence, technology platforms, and consulting. Broad incumbent operating across all major geographies and therapeutic areas; competes directly with A2 for global sponsors and Japan-specific programs while bringing substantially greater scale.
• Medipal Holdings: Japanese pharma distribution and services conglomerate with CRO operations and similar Itochu-adjacent corporate backing. Comparable as a Japan-headquartered life sciences services platform with overlapping pharma distribution and clinical services offerings.
• Syneos Health: Global full-service biopharmaceutical services organization combining clinical research with commercial solutions. Broad incumbent in the same CRO category as A2, with overlapping Phase I-IV offerings and a larger global commercial footprint.

Direct peers

• CMIC Group: Japan's largest domestic CRO offering full-service clinical development, PMS, and Site Management Organization (SMO) services. Directly comparable as a full-service Japan-based CRO with overlapping client base in domestic pharma and emerging biotech.
• ICON plc: Global top-3 CRO with headquarters in Dublin, Ireland, and a confirmed strategic partnership with A2 Healthcare for international joint trials. Direct peer in full-service clinical development with overlapping therapeutic-area expertise and a global site footprint A2 partners with for outbound trials.
• EPS Holdings: Japanese CRO and SMO providing clinical research, PMS, and healthcare consulting services. Comparable as a Tokyo-headquartered mid-to-large CRO serving similar pharma and biotech client segments across Phase I-IV and post-marketing.

Emerging players

• Hangzhou Tigermed: China-headquartered CRO expanding aggressively into Asia-Pacific and global clinical trial services. Emerging regional peer with comparable end-to-end clinical development and biostatistics offerings, growing Japan-relevant presence for cross-border pharma trials.
• Worldwide Clinical Trials: Mid-sized global CRO focused on complex therapeutic areas including oncology and CNS — both core specialties for A2. Comparable as a mid-tier competitor competing for similar emerging biotech and specialty pharma engagements across multi-region trials.

Others

• Viedoc Technologies: Sweden-based EDC vendor and A2's co-development partner for the Kondo-method RBM solution. Adjacent ecosystem participant rather than a direct competitor — provides the technology distribution channel that scales A2's proprietary methodology globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/a2healthcare

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A2 Healthcare